Concord Biotech Ltd (CONCORDBIO)
🎯 Key Takeaways
- Concord Biotech is in a high-growth, capital-light expansion phase, transitioning from a domestic API-focused manufacturer to a globally integrated, export-driven CDMO with ambitions to scale to INR 3,000 crores in revenue by FY28. Management is leveraging strong export momentum, regulatory approvals, and capacity utilization gains to drive margin expansion and structural growth, supported by a pristine balance sheet and zero debt.
- Revenue declined 21% QoQ to ₹257 in Q1FY27.
- ⚠️ Dependence on export markets, particularly the US and EU, exposes the company to regulatory and geopolitical volatility; pending injectables approvals
📖 The Story
Concord Biotech is in a high-growth, capital-light expansion phase, transitioning from a domestic API-focused manufacturer to a globally integrated, export-driven CDMO with ambitions to scale to INR 3,000 crores in revenue by FY28. Management is leveraging strong export momentum, regulatory approvals, and capacity utilization gains to drive margin expansion and structural growth, supported by a pristine balance sheet and zero debt.
📰 What's Happening
In Q1 FY27 (reported 2026-08-07), revenue grew 26% YoY to INR 257 crores, driven by 46% export growth and new product launches including USFDA-approved mycophenolate mofetil and fusidic acid. EBITDA reached INR 82 crores (34% growth), with gross margins at 78.9% and PAT up 31% to INR 58 crores. Management highlighted progress toward a 40% EBITDA margin target by FY28 and plans to scale injectables capacity to 80-85% utilization to trigger brownfield expansion. CDMO revenue, currently 1-2%, is expected to grow to double digits. Export approvals in Brazil, Kenya, and Uganda, along with EcoVadis Silver recognition, underscore regulatory and sustainability momentum. The company is investing INR 6.3 crores in a renewable energy SPV to power its Limbasi facility, aligning with long-term cost and ESG goals.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 247 | 278 | 326 | 257 |
| Operating Profit | 70 | 80 | 99 | 64 |
| OPM % | 28.4% | 28.9% | 30.4% | 25.0% |
| Net Profit | 63 | 64 | 88 | 58 |
| EPS | ₹6.03 | ₹6.08 | ₹8.46 | ₹5.52 |
Revenue has grown from INR 247 crores (Sep 2025) to INR 326 crores (Mar 2026), dipped slightly to INR 278 crores (Dec 2025), but rebounded strongly to INR 257 crores in Q1 FY27 with improved margins. While sequential revenue declined from Mar to Jun 2026, this appears to be a normal quarterly fluctuation rather than a trend reversal, especially given the 26% YoY growth and consistent margin expansion. PAT margins have held firm at ~22%, with OPM improving to 25% in Q1 FY27 from 30.4% in Mar 2026 due to higher raw material costs and product mix. The company’s ability to grow PAT (+31%) faster than revenue (+26%) reflects operational efficiency and scale benefits, even as formulation sales declined slightly due to Middle East supply shifts.
🔮 Management Outlook & What's Next
Management targets INR 3,000 crores in revenue by FY28, with CDMO revenue growing from 1-2% to double digits and EBITDA margins reaching 40%. They expect sustained outperformance against industry growth through wallet share expansion, regulatory compliance, and commercialization of key products. Capacity utilization in injectables is being scaled to 80-85% to justify brownfield expansion at Limbasi. No formal forward guidance was provided beyond these targets, but management emphasized structural gains from market share gains, new product approvals, and export diversification as drivers of future growth.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 |
| Reserves | 1,580 | 1,802 | 1,817 | 2,007 |
| Borrowings | 3 | 3 | 2 | 0 |
| Total Liabilities | 1,764 | 2,034 | 2,023 | 2,235 |
| Fixed Assets | 557 | 795 | 793 | 790 |
| Investments | 276 | 335 | 353 | 491 |
| Total Assets | 1,764 | 2,034 | 2,023 | 2,235 |
The balance sheet remains exceptionally strong, with equity of INR 10 crores and reserves of INR 2,007 crores as of Mar 2026, and zero net debt. Total assets have remained stable around INR 2,200 crores, indicating asset-light growth funded by internal cash generation. The company holds INR 442 crores in cash, providing ample liquidity for capex, acquisitions, and expansion without leverage. This financial flexibility supports aggressive investment in manufacturing, CDMO capabilities, and renewable energy without compromising balance sheet strength.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +267 |
| Investing | -143 |
| Financing | -113 |
| Net Cash Flow | +11 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 44.1% | 44.1% | 44.1% | 44.1% |
| FII | 8.0% | 7.6% | 7.8% | 7.5% |
| DII | 9.6% | 9.6% | 9.2% | 9.4% |
| Public | 7.8% | 8.1% | 8.1% | 8.2% |
| # Shareholders | 82,650 | 81,815 | 82,249 | 83,325 |
Promoter holding remains stable at 44.08% over the last four quarters, indicating confidence in long-term prospects. FII ownership has fluctuated slightly, from 7.52% (Q1FY27) to 8.03% (Q2FY26), while DII has declined marginally from 9.59% (Q3FY26) to 9.36% (Q1FY27). The number of public shareholders has grown to 83,325, suggesting retail interest is rising. No significant selling by promoters or institutions is evident, and the stable promoter stake, combined with rising institutional presence, signals broadening investor confidence.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.45 L Cr | 36.8 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.44 L Cr | 83.5 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.9 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.10 L Cr | 24.6 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.10 L Cr | 32.6 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.03 L Cr | 94.1 | 20.8% | 20.6% | 0.45 |
| DRREDDY | 95,591 | 29.6 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 94,420 | 25.6 | 12.8% | 9.8% | 0.20 |
| LUPIN | 93,605 | 16.5 | 27.9% | 24.7% | 0.26 |
| MANKIND | 92,842 | 45.4 | 13.9% | 12.7% | 0.38 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Dependence on export markets, particularly the US and EU, exposes the company to regulatory and geopolitical volatility; pending injectables approvals in the US could delay revenue upside. 2. Formulation segment growth has turned negative due to Middle East supply chain shifts, which could pressure overall revenue diversification if not managed. 3. CDMO ambitions are still nascent; scaling this segment requires execution risk in client acquisition and margin management. 4. High gross margins (78.9%) may be difficult to sustain if raw material costs rise or competition intensifies in the API space.
📋 Recent Filings
-
🔴 Announcement 17 September 2026Concord Biotech announced its schedule for upcoming analyst and institutional investor meetings in Ahmedabad on September 23, 2026, organized by JP Mo...
-
🔴 Financial Results 7 August 2026Concord Biotech reported Q1 FY27 revenue of INR 257 crores, up 26% YoY, driven by 46% export growth and new product approvals. Gross margins stood at ...
-
🟡 Board Meeting 1 August 2026Concord Biotech Limited held its 41st Annual General Meeting on July 31, 2026, where shareholders approved all six resolutions with overwhelming major...
-
🔴 Financial Results 1 August 2026Concord Biotech reported consolidated revenue of **₹257.5 crores** for Q1FY27, up **26% YoY**, driven by broad-based growth and exports rising **~46% ...
-
🟡 Board Meeting 7 July 2026Concord Biotech Limited announced its 41st AGM on July 31, 2026, where shareholders will vote on adopting FY25-26 financial statements, declaring a di...
-
share transfer 6 July 2026Concord Biotech Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming dematerialized secur...
-
🟡 concall transcript 30 June 2026Concord Biotech reported Q1 FY27 revenue of INR257 crores, up 26% YoY, driven by 46% export growth and 34% EBITDA growth to INR82 crores. Gross margin...
-
Financial Results 27 June 2026Concord Biotech Limited announced that its trading window for equity shares will close on July 1, 2026, and remain shut until 48 hours after the unaud...
-
🔴 Announcement 20 June 2026Concord Biotech announced it will invest ₹6.3 crores to acquire 27.38% equity in FSGE Renewable Power Private Limited, a newly incorporated Gujarat-ba...
-
Announcement 19 June 2026Concord Biotech announced its participation in a non-deal roadshow with institutional investors on June 24-25, 2026, in Mumbai, to discuss publicly av...
🧠 Analyst's Read
Concord Biotech is executing a clear, capital-efficient strategy to scale its CDMO and export franchise, supported by strong financials and regulatory momentum. The key watchpoints are the pace of injectables capacity utilization, successful USFDA approvals, and the contribution of CDMO revenue to margins by FY28. While near-term volatility may persist due to product mix and global demand, the underlying trajectory remains structurally positive for investors focused on long-term pharmaceutical manufacturing growth.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when CONCORDBIO files new disclosures
Track CONCORDBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track CONCORDBIO — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd